{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:53Z","timestamp":1780791113505,"version":"3.54.1"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin\/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of this study was to determine serum PCSK9 concentrations during and after DAA therapy to identify associations with LDL levels. Serum PCSK9 was increased in 82 chronic HCV-infected patients compared to 55 patients not infected with HCV. Serum PCSK9 was low in HCV patients with liver cirrhosis, but patients with HCV-induced liver cirrhosis still exhibited higher serum PCSK9 than patients with non-viral liver cirrhosis. Serum PCSK9 correlated with measures of liver injury and inflammation in cirrhotic HCV patients. In patients without liver cirrhosis, a positive association of serum PCSK9 with viral load existed. Serum PCSK9 was not different between viral genotypes. Serum PCSK9 did not correlate with LDL levels in HCV patients irrespective of cirrhotic status. Serum PCSK9 was reduced, and LDL was increased at four weeks after DAA therapy start in non-cirrhotic HCV patients. Serum PCSK9 and LDL did not change upon DAA treatment in the cirrhotic group. The rapid decline of PCSK9 after the start of DAA therapy in conjunction with raised LDL levels in non-cirrhotic HCV patients shows that these changes are not functionally related.<\/jats:p>","DOI":"10.3390\/jcm10081621","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T03:04:06Z","timestamp":1618196646000},"page":"1621","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rapid Decline of Serum Proprotein Convertase Subtilisin\/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy"],"prefix":"10.3390","volume":"10","author":[{"given":"Jonathan","family":"Grimm","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Peschel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Schacherer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Wiest","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, University Inselspital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Weigand","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hep.20030","article-title":"Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth","volume":"39","author":"Casiraghi","year":"2004","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e22726","DOI":"10.1097\/MD.0000000000022726","article-title":"Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/jgh.15280","article-title":"Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients","volume":"36","author":"Nakajima","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Peschel, G., Grimm, J., Gulow, K., Muller, M., Buechler, C., and Weigand, K. (2020). Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics, 10.","DOI":"10.3390\/diagnostics10110974"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.aohep.2020.03.002","article-title":"Viral eradication restores normal iron status in chronic hepatitis C patients with abnormal iron studies","volume":"19","author":"Hasan","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10620-019-06035-1","article-title":"The Moral of Hepatic Fibrosis: Don\u2019t Always Believe Noninvasive Fibrosis Measurements","volume":"65","author":"Enomoto","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1128\/JVI.02727-13","article-title":"Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation","volume":"88","author":"Syed","year":"2014","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-021-01431-x","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis","volume":"20","author":"Feder","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/gut.2005.069757","article-title":"Steatosis in chronic hepatitis C: Why does it really matter?","volume":"55","author":"Asselah","year":"2006","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","article-title":"Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease","volume":"126","author":"Lonardo","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hashimoto, S., Yatsuhashi, H., Abiru, S., Yamasaki, K., Komori, A., Nagaoka, S., Saeki, A., Uchida, S., Bekki, S., and Kugiyama, Y. (2016). Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163644"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Santulli, G., Jankauskas, S.S., and Gambardella, J. (2021). Inclisiran: A new milestone on the PCSK9 road to tackle cardiovascular risk. Eur. Heart J. Cardiovasc. Pharm.","DOI":"10.1093\/ehjcvp\/pvab014"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: The era of rna-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/jcmm.13273","article-title":"Hepatitis C virus and proprotein convertase subtilisin\/kexin type 9: A detrimental interaction to increase viral infectivity and disrupt lipid metabolism","volume":"21","author":"Pirro","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1099\/jgv.0.000987","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A","volume":"99","author":"Li","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ramanathan, A., Gusarova, V., Stahl, N., Gurnett-Bander, A., and Kyratsous, C.A. (2016). Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154498"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fasolato, S., Pigozzo, S., Pontisso, P., Angeli, P., Ruscica, M., Savarino, E., De Martin, S., Lupo, M.G., and Ferri, N. (2020). PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103134"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Buechler, C., Haberl, E.M., Rein-Fischboeck, L., and Aslanidis, C. (2017). Adipokines in Liver Cirrhosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071392"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","article-title":"PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism","volume":"62","author":"Bridge","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","article-title":"Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b","volume":"23","author":"Endo","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_27","first-page":"156","article-title":"Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir\/Asunaprevir","volume":"10","author":"Ichikawa","year":"2019","journal-title":"Biomed. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e16270","DOI":"10.1097\/MD.0000000000016270","article-title":"Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice","volume":"98","author":"Yen","year":"2019","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease","volume":"49","author":"Butt","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15074","DOI":"10.1038\/s41598-018-33536-2","article-title":"Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma","volume":"8","author":"Ho","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.6061\/clinics\/2017(09)01","article-title":"Accuracy of transient elastography-FibroScan(R), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C","volume":"72","author":"Ragazzo","year":"2017","journal-title":"Clinics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15385","DOI":"10.1038\/s41598-019-51673-0","article-title":"Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum","volume":"9","author":"Rajan","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e002683","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent \u201cPCSK9-Lipid Paradox\u201d","volume":"5","author":"Kohli","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1194\/jlr.P009860","article-title":"Fasting reduces plasma proprotein convertase, subtilisin\/kexin type 9 and cholesterol biosynthesis in humans","volume":"51","author":"Browning","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3945\/jn.116.235069","article-title":"Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors","volume":"147","author":"Krysa","year":"2017","journal-title":"J. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arter. Thromb Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid Lowering Therapy and Circulating PCSK9 Concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults with Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999\u20132014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schlegel, V., Treuner-Kaueroff, T., Seehofer, D., Berg, T., Becker, S., Ceglarek, U., Thiery, J., and Kaiser, T. (2017). Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181540"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-015-0371-6","article-title":"Decreased PCSK9 expression in human hepatocellular carcinoma","volume":"15","author":"Bhat","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10753-019-01114-x","article-title":"Inhibition of Proprotein Convertase Subtilisin\/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia","volume":"43","author":"Zou","year":"2020","journal-title":"Inflammation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"158792","DOI":"10.1016\/j.bbalip.2020.158792","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40119-017-0092-8","article-title":"Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients","volume":"6","author":"Toth","year":"2017","journal-title":"Cardiol. Ther."},{"key":"ref_49","first-page":"939","article-title":"Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection","volume":"20","author":"Giannelli","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.23299","article-title":"Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review","volume":"43","author":"Babiker","year":"2020","journal-title":"Clin. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: A narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Heinzl, M.W., Resl, M., Klammer, C., Egger, M., Dieplinger, B., and Clodi, M. (2020). Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response. Infect. Immun., 88.","DOI":"10.1128\/IAI.00842-19"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.08.020","article-title":"Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin\/Kexin Type 9","volume":"23","author":"Hyrina","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2796.2009.02167.x","article-title":"The unique role of proprotein convertase subtilisin\/kexin 9 in cholesterol homeostasis","volume":"266","author":"Mousavi","year":"2009","journal-title":"J. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/tcmj.tcmj_247_19","article-title":"Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C","volume":"32","author":"Kuo","year":"2020","journal-title":"Tzu Chi Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: From Basic Science Discoveries to Clinical Trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"59666","DOI":"10.18632\/oncotarget.19611","article-title":"Statins and the risk of cirrhosis in hepatitis B or C patients: A systematic review and dose-response meta-analysis of observational studies","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:12:21Z","timestamp":1760364741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["jcm10081621"],"URL":"https:\/\/doi.org\/10.3390\/jcm10081621","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]}}}